These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 17532963

  • 1. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
    Tardif JC, Carrier M, Kandzari DE, Emery R, Cote R, Heinonen T, Zettler M, Hasselblad V, Guertin MC, Harrington RA, MEND-CABG Investigators.
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
    Mehta RH, Alexander JH, Emery R, Ellis SJ, Hasselblad V, Khalil A, Carrier M, Harrington RA, Tardif JC, MEND-CABG II Investigators.
    Am Heart J; 2008 Apr; 155(4):600-8. PubMed ID: 18371465
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
    MEND-CABG II InvestigatorsDuke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715 , USA. john.h.alexander@duke.edu, Alexander JH, Emery RW, Carrier M, Ellis SJ, Mehta RH, Hasselblad V, Menasche P, Khalil A, Cote R, Bennett-Guerrero E, Mack MJ, Schuler G, Harrington RA, Tardif JC.
    JAMA; 2008 Apr 16; 299(15):1777-87. PubMed ID: 18381567
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
    Carrier M, Ménasché P, Levy JH, Newman MF, Taylor KM, Haverich A, Chen JC, Shernan SK, Van de Werf F, van der Laan M, Todaro TG, Adams PX, Verrier ED.
    J Thorac Cardiovasc Surg; 2006 Feb 16; 131(2):352-6. PubMed ID: 16434264
    [Abstract] [Full Text] [Related]

  • 5. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
    Carrier M, Emery R, Kandzari DE, Harrington R, Guertin MC, Tardif JC.
    J Cardiovasc Surg (Torino); 2008 Apr 16; 49(2):249-53. PubMed ID: 18431346
    [Abstract] [Full Text] [Related]

  • 6. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
    Smith PK, Carrier M, Chen JC, Haverich A, Levy JH, Menasché P, Shernan SK, Van de Werf F, Adams PX, Todaro TG, Verrier E.
    Ann Thorac Surg; 2006 Sep 16; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
    [Abstract] [Full Text] [Related]

  • 7. Translational research: is there a future?
    Verrier ED.
    J Thorac Cardiovasc Surg; 2007 Jun 16; 133(6):1409-11. PubMed ID: 17532929
    [No Abstract] [Full Text] [Related]

  • 8. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT, Pexelizumab Study Investigators.
    Ann Thorac Surg; 2004 Mar 16; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [Abstract] [Full Text] [Related]

  • 9. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
    Haverich A, Shernan SK, Levy JH, Chen JC, Carrier M, Taylor KM, Van de Werf F, Newman MF, Adams PX, Todaro TG, van der Laan M, Verrier ED.
    Ann Thorac Surg; 2006 Aug 16; 82(2):486-92. PubMed ID: 16863750
    [Abstract] [Full Text] [Related]

  • 10. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves.
    Ramsay J, Shernan S, Fitch J, Finnegan P, Todaro T, Filloon T, Nussmeier NA.
    J Thorac Cardiovasc Surg; 2005 Feb 16; 129(2):300-6. PubMed ID: 15678039
    [Abstract] [Full Text] [Related]

  • 11. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
    Collard CD, Body SC, Shernan SK, Wang S, Mangano DT, Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc, Ischemia Research and Education Foundation (IREF) Investigators.
    J Thorac Cardiovasc Surg; 2006 Aug 16; 132(2):392-400. PubMed ID: 16872968
    [Abstract] [Full Text] [Related]

  • 12. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.
    El-Hamamsy I, Stevens LM, Carrier M, Pellerin M, Bouchard D, Demers P, Cartier R, Page P, Perrault LP.
    J Thorac Cardiovasc Surg; 2007 Jan 16; 133(1):7-12. PubMed ID: 17198774
    [Abstract] [Full Text] [Related]

  • 13. Biochemical assessment of myocardial injury after cardiac surgery: effects of a platelet activating factor antagonist, bilateral internal thoracic artery grafts, and coronary endarterectomy.
    Taggart DP.
    J Thorac Cardiovasc Surg; 2000 Oct 16; 120(4):651-9. PubMed ID: 11003744
    [Abstract] [Full Text] [Related]

  • 14. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
    Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH, IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators.
    Circulation; 2008 Jan 01; 117(1):24-31. PubMed ID: 18071079
    [Abstract] [Full Text] [Related]

  • 15. The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass grafting surgery is time and magnitude limited.
    Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A.
    Eur J Cardiothorac Surg; 2005 Jul 01; 28(1):114-9. PubMed ID: 15982595
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
    Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, ARMYDA Investigators.
    Circulation; 2004 Aug 10; 110(6):674-8. PubMed ID: 15277322
    [Abstract] [Full Text] [Related]

  • 17. Myocardial injury in coronary artery bypass grafting: on-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release.
    Chowdhury UK, Malik V, Yadav R, Seth S, Ramakrishnan L, Kalaivani M, Reddy SM, Subramaniam GK, Govindappa R, Kakani M.
    J Thorac Cardiovasc Surg; 2008 May 10; 135(5):1110-9, 1119.e1-10. PubMed ID: 18455592
    [Abstract] [Full Text] [Related]

  • 18. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events.
    Berg HF, Maraha B, Scheffer GJ, Quarles-van Ufford M, Vandenbroucke-Grauls CM, Peeters MF, Kluytmans JA.
    Clin Infect Dis; 2005 Feb 01; 40(3):358-65. PubMed ID: 15668857
    [Abstract] [Full Text] [Related]

  • 19. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies.
    Rastan AJ, Eckenstein JI, Hentschel B, Funkat AK, Gummert JF, Doll N, Walther T, Falk V, Mohr FW.
    Circulation; 2006 Jul 04; 114(1 Suppl):I477-85. PubMed ID: 16820622
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.
    Diabetes Care; 2006 Jul 04; 29(7):1478-85. PubMed ID: 16801565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.